EP3826649A4 - Verfahren zur behandlung von neurologischen störungen - Google Patents

Verfahren zur behandlung von neurologischen störungen Download PDF

Info

Publication number
EP3826649A4
EP3826649A4 EP19839881.0A EP19839881A EP3826649A4 EP 3826649 A4 EP3826649 A4 EP 3826649A4 EP 19839881 A EP19839881 A EP 19839881A EP 3826649 A4 EP3826649 A4 EP 3826649A4
Authority
EP
European Patent Office
Prior art keywords
methods
neurological disorders
treating neurological
treating
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19839881.0A
Other languages
English (en)
French (fr)
Other versions
EP3826649A1 (de
Inventor
Manuel A. Navia
Kasper ROET
Jonathan J. FLEMING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enclear Therapies Inc
Original Assignee
Enclear Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enclear Therapies Inc filed Critical Enclear Therapies Inc
Publication of EP3826649A1 publication Critical patent/EP3826649A1/de
Publication of EP3826649A4 publication Critical patent/EP3826649A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/2102—Cathepsin G (3.4.21.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
EP19839881.0A 2018-07-23 2019-07-22 Verfahren zur behandlung von neurologischen störungen Pending EP3826649A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862702188P 2018-07-23 2018-07-23
US201862702191P 2018-07-23 2018-07-23
US201962815123P 2019-03-07 2019-03-07
PCT/US2019/042879 WO2020023417A1 (en) 2018-07-23 2019-07-22 Methods of treating neurological disorders

Publications (2)

Publication Number Publication Date
EP3826649A1 EP3826649A1 (de) 2021-06-02
EP3826649A4 true EP3826649A4 (de) 2022-07-20

Family

ID=69181950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19839881.0A Pending EP3826649A4 (de) 2018-07-23 2019-07-22 Verfahren zur behandlung von neurologischen störungen

Country Status (7)

Country Link
US (1) US11752200B2 (de)
EP (1) EP3826649A4 (de)
JP (1) JP2022510573A (de)
CN (1) CN113164563A (de)
AU (1) AU2019310039A1 (de)
CA (1) CA3107349A1 (de)
WO (1) WO2020023417A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019310039A1 (en) 2018-07-23 2021-02-18 Enclear Therapies, Inc. Methods of treating neurological disorders
CN113164557A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 治疗神经性病症的方法
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ， インク． 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
US20220202716A1 (en) * 2019-04-15 2022-06-30 Nanologica Ab Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145428A2 (en) * 2011-04-21 2012-10-26 Washington University Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid
WO2014124365A2 (en) * 2013-02-08 2014-08-14 Cornell University Biomolecular processing platform and uses thereof

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4830849A (en) 1980-04-14 1989-05-16 Thomas Jefferson University Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4382445A (en) 1980-12-04 1983-05-10 Cosmos Research Associates Physiological fluid shunt system and improvements therefor
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4650760A (en) * 1985-01-22 1987-03-17 Research Corporation Modified alkaline phosphatase
US4655745A (en) 1985-07-29 1987-04-07 Corbett Joseph E Ventricular catheter
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4950232A (en) 1987-08-11 1990-08-21 Surelab Superior Research Laboratories Cerebrospinal fluid shunt system
JP3134121B2 (ja) 1989-10-11 2001-02-13 バクスター インターナショナル インコーポレーテッド 頭蓋内圧モニターおよび排液カテーテルアセンブリー
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
GB9103430D0 (en) 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5405316A (en) 1993-11-17 1995-04-11 Magram; Gary Cerebrospinal fluid shunt
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US20030044396A1 (en) 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
US6136548A (en) 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5531673A (en) 1995-05-26 1996-07-02 Helenowski; Tomasz K. Ventricular catheter
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US20060025726A1 (en) 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
ES2183191T3 (es) 1996-06-04 2003-03-16 Cook Inc Dispositivo medico implantable.
US20040068241A1 (en) 1996-06-04 2004-04-08 Fischer Frank J. Implantable medical device
US6689085B1 (en) 1996-07-11 2004-02-10 Eunoe, Inc. Method and apparatus for treating adult-onset dementia of the Alzheimer's type
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6030358A (en) 1997-08-08 2000-02-29 Odland; Rick Matthew Microcatheter and method for site specific therapy
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US5957912A (en) 1998-04-16 1999-09-28 Camino Neurocare, Inc. Catheter having distal stylet opening and connector
EP1178800A4 (de) * 1999-03-24 2002-07-31 Univ California Verfahren zur Behandlung von Neurodegenerativen Störungen unter Verwendung der Inhibitoren von Aspartyl-Protease
US6193691B1 (en) 1999-03-30 2001-02-27 Depuy Orthopaedics, Inc. Catheter system
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
EP1244800B1 (de) 1999-10-29 2007-03-14 Kosan Biosciences, Inc. Rapamycin analoge
US20020025521A1 (en) 1999-11-29 2002-02-28 Lu Kun Ping Pin1 as a marker for abnormal cell growth
US7769420B2 (en) 2000-05-15 2010-08-03 Silver James H Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction
AU2001281250A1 (en) * 2000-08-11 2002-02-25 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2002070036A2 (en) 2001-03-01 2002-09-12 Watson David A Ingrowth preventing indwelling catheter assembly
US7025739B2 (en) 2001-08-09 2006-04-11 Integra Lifesciences Corporation System and method for treating elevated intracranial pressure
AU2002313778A1 (en) 2001-08-21 2003-03-03 Eunoe, Inc. Combined drug and csf removal therapies and systems
CN1615137A (zh) 2002-01-10 2005-05-11 诺瓦提斯公司 用于预防和治疗血管疾病、包含雷帕霉素及其衍生物的药物递送***
US6913589B2 (en) 2002-01-14 2005-07-05 Codman & Shurtleff, Inc. Multi-catheter insertion device and method
US7037288B2 (en) 2002-01-14 2006-05-02 Codman & Shurtleff, Inc. Anti-block catheter
AU2003249682A1 (en) 2002-06-03 2003-12-19 Als Therapy Development Foundation Treatment of neurodegenerative diseases using proteasome modulators
US20040220548A1 (en) 2002-12-23 2004-11-04 Medtronic, Inc. Permeable membrane catheters, systems, and methods
ATE422164T1 (de) 2003-02-18 2009-02-15 Medtronic Inc Verschlussbeständiger hydrocephalischer shunt
US20040185042A1 (en) * 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
US20040236309A1 (en) 2003-05-19 2004-11-25 Benson Yang Mesh ventricular catheter with antithrombogenic coating
US7686780B2 (en) 2003-09-26 2010-03-30 New York University System and method for correction of intracerebral chemical imbalances
US8057401B2 (en) 2005-02-24 2011-11-15 Erich Wolf System for transcutaneous monitoring of intracranial pressure
JP4964771B2 (ja) 2004-07-20 2012-07-04 メドトロニック，インコーポレイテッド 脳脊髄液排液装置
US9097723B2 (en) * 2005-04-01 2015-08-04 Caliper Life Sciences, Inc. Method and apparatus for performing peptide digestion on a microfluidic device
US20070173787A1 (en) 2005-11-01 2007-07-26 Huang Mark C T Thin-film nitinol based drug eluting stent
US8206334B2 (en) 2006-01-31 2012-06-26 Kralick Francis A Implantable micro-system for treatment of hydrocephalus
US20080082036A1 (en) 2006-04-25 2008-04-03 Medtronic, Inc. Cerebrospinal fluid shunt having long term anti-occlusion agent delivery
US9770180B2 (en) 2006-08-17 2017-09-26 Milan Radojicic System and method for monitoring and delivering therapeutics to the spinal cord
US20080051691A1 (en) 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
EP2086573B1 (de) 2006-10-09 2020-11-25 Neurofluidics, Inc. System zur reinigung von liquor
US10695545B2 (en) 2006-10-09 2020-06-30 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid
TW200907056A (en) 2007-03-28 2009-02-16 Astrazeneca Ab New method
US8501695B2 (en) * 2007-07-20 2013-08-06 Diamedica, Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US7887503B2 (en) 2007-11-20 2011-02-15 Mark Geiger Method and apparatus for removing harmful proteins from a mammalian's ventricular cerebrospinal fluid
EP2320987A1 (de) 2008-07-29 2011-05-18 Medtronic, Inc. Apherese eines zielmoleküls aus liquor
US20170157038A1 (en) 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method
US20110033463A1 (en) 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
JP2013516497A (ja) 2010-01-11 2013-05-13 ミスリィディオン，インク． 認知増強のための化合物と組成物、製造方法、および治療方法
WO2011114260A1 (en) 2010-03-19 2011-09-22 Pfizer Inc. Cerebrospinal fluid purification system
CA2809916A1 (en) * 2010-10-01 2012-04-05 Novozymes A/S Polypeptides having endopeptidase activity and polynucleotides encoding same
EP2647720B1 (de) 2010-12-03 2019-06-19 The University of Tokyo Peptidbibliothek-herstellungsverfahren, peptidbibliothek und screening-verfahren
US20120238837A1 (en) 2011-03-16 2012-09-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System, devices, and methods for real-time monitoring of cerebrospinal fluid for markers of progressive conditions
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
AU2014209548B2 (en) 2013-01-22 2018-08-23 Anuncia, Inc Systems and methods for shunting fluid
EP2948471A4 (de) 2013-01-24 2016-08-10 Mayo Foundation Verfahren und materialien zur erkennung der positiven frontotemporallappen-degeneration durch c9orf72-hexanukleotid-repeat-expansion oder von amyotropher lateralsklerose durch c9orf72-hexanukleotid-repeat-expansion
CN104902941B (zh) 2013-02-12 2017-05-03 东丽株式会社 血液净化柱
CA2904960A1 (en) 2013-03-14 2014-10-02 University Of Florida Research Foundation, Inc. Di-amino acid repeat-containing proteins associated with als
US20140303455A1 (en) 2013-04-03 2014-10-09 Pharmaco-Kinesis Corporation Multipurpose cerebrospinal fluid sensor assembly and method of operation of the same
US9421348B2 (en) 2013-10-01 2016-08-23 Ecole Polytechnique Federale De Lausanne (Epfl) Systems and methods for moving and circulating fluid to treat alzheimer's disease
AU2015247353B2 (en) 2014-04-18 2020-07-09 Anuncia, Inc Systems and methods for shunting fluid
US10272188B1 (en) 2014-07-23 2019-04-30 Mensanan Therapeutics LLC Cerebrospinal fluid treatment
KR20180026669A (ko) 2015-05-15 2018-03-13 리빙 셀 테크놀로지스 뉴질랜드 리미티드 캡슐화된 유도성 맥락총 세포를 사용한 cns 질환의 치료
WO2016210136A2 (en) 2015-06-23 2016-12-29 Advanced Csf Therapies, Llc Methods and system for ultrasonic targeted drug delivery in cystic fluids, such as the cerebrospinal fluid, using buoyancy specific drug carriers
US11091533B2 (en) * 2015-11-13 2021-08-17 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
CN108778355B (zh) 2015-12-04 2021-04-30 米奈特朗尼克斯有限公司 用于对脑脊液进行调节的***及方法
US10759830B2 (en) * 2015-12-09 2020-09-01 The Uab Research Foundation Bacterial colicin-immunity protein protein purification system
US11529443B2 (en) 2015-12-28 2022-12-20 Cognos Therapeutics Inc. Apparatus and method for cerebral microdialysis to treat neurological disease, including Alzheimer's, Parkinson's or multiple sclerosis
WO2018005621A1 (en) 2016-06-29 2018-01-04 The Penn State Research Foundation Devices and methods for accessing subarachnoid space
EP3490653A1 (de) 2016-07-28 2019-06-05 Cerebral Therapeutics Implantierbare intraventrikuläre probenahme- und infusionszugangsvorrichtung
AU2017383551B2 (en) 2016-12-19 2022-01-27 Enzymocore Ltd. Enzymatic enrichment of n-3 fatty acids in the form of glycerides
CN110022916B (zh) 2016-12-21 2022-06-03 亚克安娜治疗学有限公司 药物递送***和方法
EP3457567B1 (de) 2017-09-15 2020-11-25 Socionext Inc. Phasenabgleich
US20200330497A1 (en) 2017-10-19 2020-10-22 Elysium Health, Inc. Prevention and treatment of tdp-43 associated diseases
AU2019310039A1 (en) 2018-07-23 2021-02-18 Enclear Therapies, Inc. Methods of treating neurological disorders
CN113164557A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 治疗神经性病症的方法
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ， インク． 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
US20210033620A1 (en) * 2019-07-29 2021-02-04 University Of Utah Immobilized Enzymatic Digestion of Blood Products for Diagnostic Testing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145428A2 (en) * 2011-04-21 2012-10-26 Washington University Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid
WO2014124365A2 (en) * 2013-02-08 2014-08-14 Cornell University Biomolecular processing platform and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KIM KWANG SOO ET AL: "Proteolytic Cleavage of Extracellular [alpha]-Synuclein by Plasmin", vol. 287, no. 30, 22 March 2012 (2012-03-22), US, pages 24862 - 24872, XP055929127, ISSN: 0021-9258, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408156/pdf/zbc24862.pdf> DOI: 10.1074/jbc.M112.348128 *
KUNIKAZU TANJI ET AL: "Proteinase K-resistant Î -synuclein is deposited in presynapses in human Lewy body disease and A53T Î -synuclein transgenic mice", ACTA NEUROPATHOLOGICA, SPRINGER, BERLIN, DE, vol. 120, no. 2, 26 March 2010 (2010-03-26), pages 145 - 154, XP019846998, ISSN: 1432-0533 *
SAIDO T. ET AL: "Proteolytic Degradation of Amyloid -Protein", vol. 2, no. 6, 1 June 2012 (2012-06-01), pages a006379 - a006379, XP055928975, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367539/pdf/cshperspectmed-ALZ-a006379.pdf> DOI: 10.1101/cshperspect.a006379 *
SPENCER BRIAN ET AL: "Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type [alpha]-Synuclein and Reduces the Pathology in an [alpha]-Synuclein Model of LBD", vol. 21, no. 1, 1 January 2013 (2013-01-01), US, pages 31 - 41, XP055929153, ISSN: 1525-0016, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538325/pdf/mt201266a.pdf> DOI: 10.1038/mt.2012.66 *

Also Published As

Publication number Publication date
CA3107349A1 (en) 2020-01-30
CN113164563A (zh) 2021-07-23
EP3826649A1 (de) 2021-06-02
WO2020023417A1 (en) 2020-01-30
AU2019310039A1 (en) 2021-02-18
US20210145944A1 (en) 2021-05-20
US11752200B2 (en) 2023-09-12
JP2022510573A (ja) 2022-01-27

Similar Documents

Publication Publication Date Title
EP3746135A4 (de) Verfahren und verbindungen zur behandlung von erkrankungen
AU2016282790B9 (en) VMAT2 inhibitors for treating neurological diseases or disorders
EP3526319A4 (de) Verfahren und zusammensetzungen und zur behandlung von erkrankungen und störungen des zentralnervensystems
EP4010072A4 (de) Behandlung von erkrankungen des zentralnervensystems
EP3826650A4 (de) Verfahren zur behandlung von neurologischen erkrankungen
EP3596063A4 (de) Pyrimidinyl-pyridyloxy-naphthylverbindungen und verfahren zur behandlung von ire1-bedingten erkrankungen und störungen
EP3826649A4 (de) Verfahren zur behandlung von neurologischen störungen
EP3566055A4 (de) Verfahren zur behandlung von neurologischen erkrankungen
EP3507371A4 (de) Verfahren und zusammensetzungen und zur behandlung von erkrankungen und störungen des nervensystems
EP3810049A4 (de) Systeme und verfahren zur behandlung neurologischer erkrankungen
EP3856169A4 (de) Verfahren zur behandlung von myeloproliferativen erkrankungen
EP3740201A4 (de) Verfahren zur behandlung von säure-basen-störungen
EP3554505A4 (de) Verfahren zur behandlung von augenerkrankungen
EP3761970A4 (de) Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen
EP3621434A4 (de) Verfahren zur behandlung von neuropsychiatrischen störungen
EP3810777A4 (de) Zusammensetzungen und verfahren zur behandlung oder prävention von neurologischen erkrankungen
GB201914034D0 (en) Treatment of neurological disorders
EP3506927A4 (de) Reelin-zusammensetzungen zur behandlung von neurologischen erkrankungen
EP3856198A4 (de) Behandlung von hämatologischen störungen niedriger intensität
IL263080B (en) Treatment of neurological disorders
EP3740214A4 (de) Verfahren zur behandlung von galectin-3 abhängigen störungen
EP3735129A4 (de) Zusammensetzungen und verfahren zur behandlung von neurologischen und anderen störungen
EP3790540A4 (de) Verfahren zur behandlung oder begrenzung der entwicklung kardiovaskulärer erkrankungen im zusammenhang mit neurologischen erkrankungen
IL281589A (en) Methods for treating myeloproliferative diseases
EP3866795A4 (de) Behandlung von neurologischen erkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220621

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20220614BHEP

Ipc: C12Q 1/68 20180101ALI20220614BHEP

Ipc: C07K 16/18 20060101ALI20220614BHEP

Ipc: B01D 21/26 20060101ALI20220614BHEP

Ipc: A61K 35/28 20150101AFI20220614BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 39/00 20060101ALI20220720BHEP

Ipc: A61P 25/28 20060101ALI20220720BHEP

Ipc: A61K 38/48 20060101ALI20220720BHEP

Ipc: G01N 33/68 20060101ALI20220720BHEP

Ipc: C12Q 1/68 20180101ALI20220720BHEP

Ipc: C07K 16/18 20060101ALI20220720BHEP

Ipc: B01D 21/26 20060101ALI20220720BHEP

Ipc: A61K 35/28 20150101AFI20220720BHEP